-+ 0.00%
-+ 0.00%
-+ 0.00%

Satellos to present 6-month follow-up data from SAT-3247 Phase 2 TRAILHEAD trial at ICNMD 2026

PUBT·06/25/2026 11:00:27
Listen to the news
Satellos to present 6-month follow-up data from SAT-3247 Phase 2 TRAILHEAD trial at ICNMD 2026
  • Satellos set July 8, 2026 presentations at ICNMD in Florence for new 6-month follow-up data from its SAT-3247 program.
  • Results will be presented in the future, covering participants who completed the Phase 1b SAT-3247-CL-101 trial and rolled into the ongoing Phase 2 TRAILHEAD study.
  • SAT-3247 is an oral small-molecule candidate aimed at restoring muscle repair in Duchenne muscular dystrophy in a dystrophin-independent approach.
  • The program remains in Phase 2, with TRAILHEAD in adults, alongside the pediatric BASECAMP randomized, placebo-controlled trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606250700PRIMZONEFULLFEED9752121) on June 25, 2026, and is solely responsible for the information contained therein.